Ysios Capital, a leading European venture capital firm specialized in the biotechnology sector, announces today that it has been successfully certified under the Diversity VC Standard, a certification...
YBF III – Ysios’ largest fund to date – provides biotech ventures with the resources to develop novel and disruptive therapies for indications with high-unmet medical need, supporting pioneering...
Adcendo, a biotech company developing antibody-drug conjugates (ADCs) for the treatment of cancers, today announced the successful closing of a EUR 51 million (US$ 62 million) Series A financing. The ...
Synendos Therapeutics (Synendos), a biopharmaceutical company focused on restoring the natural functioning of the endocannabinoid system to treat Central Nervous System (CNS) disorders, announces an e...
Vivet’s second gene therapy product, VTX-803 for PFIC3, received US and European Orphan Drug Designation in May 2020.Vivet is supported by international life science investors including Novartis Ven...
Aura Biosciences, a clinical-stage oncology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the closing of an oversubsc...
Splice Bio, a gene therapy company based on technology developed in the Muir Lab at Princeton University, announced today that it has appointed JeanPhilippe Combal as Chairman of its Board of Director...
Bpifrance, Novo Holdings, Seventure, Sofinnova Partners and Ysios Capital, existing shareholders of CorWave and leading investors in life sciences, significantly increased their stake in the company. ...
Ysios Capital, a leading Spanish biotechnology venture capital firm, today announced that its portfolio company Galecto Inc. has priced its initial public offering (IPO) and is trading on the Nasdaq G...
Minoryx is backed by a syndicate of experienced investors, which includes Caixa Capital Risc, Roche Venture Fund, Ysios Capital, Kurma Partners, Fund+, Chiesi Ventures, S.R.I.W, Idinvest, SFPI-FPIM, H...
Splice Bio, a biotech company based on technology developed in the Muir Lab at Princeton University, has announced a new investment into the Company led by Ysios Capital and joined by Asabys Partners ...
The oversubscribed round was co-led by Ysios Capital and INKEF Capital; Lundbeckfonden Ventures and LSP joined the syndicate. Founding investor, BioGeneration Ventures (BGV) and the regional economic ...